青海地区非小细胞肺癌患者EGFR突变状态分析  

ANALYSIS OF EGFR MUTATION IN NON- SMALL CELL LUNG CANCER AT QINGHAI REGION

作　　者：杨启英[1] 卢天龙[1] 

机构地区：[1]青海大学附属医院检验科,青海西宁810000

出　　处：《青海医学院学报》2015年第3期145-148,共4页Journal of Qinghai Medical College

基　　金：青海省(应用)基础研究计划项目(2013-Z-735)

摘　　要：目的探讨青海地区非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)基因的突变情况。方法经病理确诊的300例NSCLC患者,采用聚合酶链反应(PCR)扩增方法检测EGFR第18、19、20和21外显子的突变情况,并行相关分析。结果 300例NSCLC患者标本EGFR(exon18)突变4例,突变率1.3%;EGFR(exon19)突变36例,突变率12.0%;EGFR(exon20)未检出;EGFR(exon21)突变54例,突变率18.0%。结论青海地区NSCLC患者EGFR基因外显子19和21的突变(体细胞突变)率较高,可接受EGFR-TKIs治疗。Objective To investigate the mutation small cell lung cancer（NSCLC） patients at Qinghai area. of epidermal growth factor receptor （EGFR） gene in non Methods 300 cases of patients with NSCLC were defined by pathological diagnosis and then using polymerase chain reaction（PCR） amplification method to detect the muta- tion in EGFR 18,19,20 and 21 exons. Results Of 300 patients with NSCLC there were 4 cases mutated in EGFR （exonl8） ,the mutation rate was 1.3% ;36 cases in EGFR mutations（exonl9） ,the mutation rate was 12.0% ;there was no mutation was found in EGFR （exon20）;54 cases mutated in EGFR （exon21）, the mutation rate was 18.0%. Conclusion The rate of mutation in exon 19 and 21 （ somatic mutation） of EGFR genes in patients with NSCLC is higher,and they can be treated with EGFR - TKIs.

关 键 词：非小细胞肺癌 表皮生长因子受体 突变 青海地区 

分 类 号：R734.2[医药卫生—肿瘤]